Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)

Summary by AI BETAClose X

Novo Nordisk announced that the CHMP has recommended EU approval for Wegovy® 7.2 mg in a single-dose pen, which demonstrated a 20.7% mean weight loss in the STEP UP trial, with approximately one-third of patients achieving 25% or greater weight loss. The company anticipates launching this new formulation in the EU in the third quarter of 2026, building on its existing availability in the US and UK. The STEP UP T2D trial showed a 14.1% mean weight loss in participants with obesity and type 2 diabetes, with the safety and tolerability profile remaining consistent with previous semaglutide trials.

Disclaimer*

UK 100

Latest directors dealings